COMPARISON
Goserelin vs Leuprolide
3 attributes held for at least one of the two. 2 differ. Each value carries the register it came from and the date that register was read.
Answer
Goserelin is authorised or registered in 9 and Leuprolide in 8 of the 10 registers read. Goserelin: highest phase Phase 4 (after approval). Leuprolide: highest phase Phase 3 (2 phase 3 trials, 0 with posted results). 179 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Goserelin | Leuprolide | |
|---|---|---|
| Registered trials differs | 449 clinicaltrials.gov · 2026-10-03 | 520 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: ZOLADEX openfda · 2026-10-03T17:23:44.062Z | FDA-approved: Vabrinty openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation | Nothing on record ema read 2026-08-31 | Nothing on record ema read 2026-08-31 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Goserelin | placebo | Leuprolide | placebo |
|---|---|---|---|---|
| Arthralgia | 38.8% | 36.2% | 27.5% | 20.9% |
| Hot flush | 35.2% | 34.7% | 68.8% | 57.3% |
| Fatigue | 26.6% | 25.5% | 42.8% | 32.8% |
| Diarrhoea | 24.5% | 19.9% | 13.9% | 8.5% |
| Back pain | 22.7% | 21.4% | 17.0% | 15.3% |
| Neutropenia | 57.9% | 6.5% | - | - |
| Neutrophil count decreased | 35.5% | 1.5% | - | - |
| Nausea | 23.1% | 19.1% | - | - |
| Anaemia | 21.8% | 11.0% | - | - |
| Leukopenia | 19.7% | 3.9% | - | - |
| Fall | - | - | 20.4% | 14.1% |
| Hypertension | - | - | 16.4% | 15.1% |
| Asthenia | - | - | 11.0% | 5.9% |
| Pain in extremity | - | - | 11.0% | 10.2% |
| Dizziness | - | - | 11.0% | 10.5% |
Trial register Goserelin: 2 placebo-controlled trials; Leuprolide: 2. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Goserelin side effects · Leuprolide side effects
LEGAL STATUS
Approval in each country read
| Country | Goserelin | Leuprolide | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Not on the register | Not on the register | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Registered | Status unknown | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Authorised | Authorised | Regulator ALIMS |
| Singapore | Registered | Registered | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
HEAD TO HEAD
179 registered trials include both
| NCT05827081 | Phase IIIb Study of Ribociclib + ET in Early Breast Cancer RECRUITING · updated 2026-10-02 |
|---|---|
| NCT03070886 | Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery ACTIVE_NOT_RECRUITING · updated 2026-09-14 |
| NCT07801898 | Neoadjuvant Endocrine Therapy Combined With Chemotherapy in ER-positive, HER2-negative Stage I-III Breast Cancer NOT_YET_RECRUITING · updated 2026-09-03 |
| NCT04557059 | A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer ACTIVE_NOT_RECRUITING · updated 2026-08-28 |
| NCT07782840 | QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant Chemotherapy NOT_YET_RECRUITING · updated 2026-08-26 |
| NCT07596212 | BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexua NOT_YET_RECRUITING · updated 2026-08-24 |
| NCT04423211 | Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging RECRUITING · updated 2026-08-19 |
| NCT04513717 | Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatm ACTIVE_NOT_RECRUITING · updated 2026-08-17 |
| NCT05050084 | Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a ACTIVE_NOT_RECRUITING · updated 2026-08-17 |
| NCT03332797 | A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estro ACTIVE_NOT_RECRUITING · updated 2026-08-13 |
| NCT04126070 | Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors ACTIVE_NOT_RECRUITING · updated 2026-08-12 |
| NCT01786265 | Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer ACTIVE_NOT_RECRUITING · updated 2026-08-11 |
| NCT07751133 | Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer NOT_YET_RECRUITING · updated 2026-08-07 |
| NCT05879926 | Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-N RECRUITING · updated 2026-08-04 |
| NCT07340619 | Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patient NOT_YET_RECRUITING · updated 2026-08-03 |
| NCT04484818 | Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICAT ACTIVE_NOT_RECRUITING · updated 2026-07-28 |
| NCT07730151 | Efficacy and Safety of Darolutamide Combined With Docetaxel and ADT as Neoadjuvant Therapy for Locally Advanced Prostate Cancer. NOT_YET_RECRUITING · updated 2026-07-28 |
| NCT06378866 | Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy RECRUITING · updated 2026-07-20 |
| NCT07706933 | Tolerability of Dalpiciclib vs. Abemaciclib/Ribociclib in Early HR+/HER2- Breast Cancer NOT_YET_RECRUITING · updated 2026-07-16 |
| NCT05498272 | Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select H ACTIVE_NOT_RECRUITING · updated 2026-07-10 |
The 20 most recently updated are listed.
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.